Last updated: February 24, 2026
What is the drug associated with NDC 60505-1003?
NDC 60505-1003 refers to a specific drug product, which is identified as Lumateperone (Caplyta). It is marketed by Intra-Cellular Therapies and approved by the FDA for the treatment of schizophrenia in adults. Lumateperone was approved in December 2019, with a novel mechanism targeting multiple pathways in the central nervous system.
Current Market Landscape
Market Size and Growth
- The global antipsychotic drugs market was valued at approximately $14.8 billion in 2021, with projections reaching $20.1 billion by 2028, at a CAGR of 4.3% (Research and Markets, 2022).
- Lumateperone’s market introduction factors include heightened demand for atypical antipsychotics with fewer side effects and novel mechanisms.
Competitive Position
- Primary competitors include risperidone, olanzapine, quetiapine, and aripiprazole.
- Lumateperone positions itself as offering a mixed profile of efficacy and reduced metabolic adverse effects compared to older agents.
Market Penetration
- Initial launch in late 2019 was gradual. As of 2022, Lumateperone’s market share remains under 2% within the antipsychotic space.
- Payer adoption and formulary inclusion remain limited but are increasing, especially in specialty and hospital settings.
Pricing Analysis
Wholesale Acquisition Cost (WAC)
- As of Q1 2023, the WAC for Lumateperone (30 mg tablets) is approximately $920 per month supply.
- This aligns with competitive pricing for new molecular entities targeting niche markets and specialty indications.
Comparison to Competitors
| Drug |
Typical Monthly Price (USD) |
Indication |
Mechanism |
| Risperidone |
~$25 |
Schizophrenia, bipolar disorder |
D2 and 5-HT2A receptor antagonism |
| Olanzapine |
~$80 |
Schizophrenia, bipolar disorder |
Dopamine and serotonin receptor antagonism |
| Quetiapine |
~$75 |
Schizophrenia, bipolar disorder |
Serotonin and dopamine receptor antagonism |
| Aripiprazole |
~$100 |
Schizophrenia, bipolar disorder |
Partial dopamine agonism |
| Lumateperone |
~$920 |
Schizophrenia |
Serotonin, dopamine, and glutamate modulation |
Pricing Dynamics and Future Trends
- The high current WAC reflects exclusivity and patent protections, which are expected to last until at least 2030.
- Discounting, copay assistance, and payor negotiations could reduce net pricing by 20-30%.
- Price increases could occur in line with inflationary trends and repositioning strategies, particularly once broader indications or combination therapies are pursued.
Regulatory and Payer Considerations
- Patent protection and exclusivity rights grant pricing power until approximately 2030.
- Given the NDA’s approval pathway, insights from similar drugs suggest market access challenges include high copayments and formulary restrictions.
- As utilization grows, payers may negotiate better discounts and tier placements in exchange for formulary access.
Revenue Projections
| Year |
Estimated Market Share |
Revenue (USD, millions) |
Notes |
| 2023 |
1.5% |
~$20 |
Initial adoption phase |
| 2024 |
3% |
~$40 |
Increased formulary acceptance |
| 2025 |
5% |
~$67 |
Broader usage, expanded indications |
| 2026 |
7% |
~$93 |
Competitive shifts, price adjustments |
| 2027 |
10% |
~$133 |
Mature market penetration |
Key Takeaways
- Lumateperone remains a high-priced niche therapy within the antipsychotic market.
- Pricing remains at a premium due to exclusivity, with potential discounts lowering net revenue.
- Market growth depends heavily on formulary acceptance, efficacy in real-world settings, and expanded indications.
- Revenue projections place early sales in the tens of millions, with potential to reach over $130 million annually by 2027 if market penetration strategies succeed.
FAQs
1. What factors influence Lumateperone pricing? Regulatory exclusivity, manufacturing costs, competition, and payer negotiations.
2. When are patent protections expected to expire? Typically around 2030, providing pricing leverage until then.
3. How does Lumateperone compare in efficacy to older antipsychotics? Clinical trials show comparable efficacy with a potentially improved side effect profile, especially concerning metabolic adverse effects.
4. What are the key barriers to market growth? Payer formulary restrictions, high list prices, and competition from well-established drugs.
5. Are there upcoming formulations or indications? As of 2023, expansion into bipolar disorder or adjunctive therapy trials remains speculative and under development.
References
- Research and Markets. (2022). Global Antipsychotic Drugs Market Analysis.
- FDA. (2019). NDA Approval Summary: Lumateperone (Caplyta).
- IQVIA. (2022). Healthcare Market Data.
- Intra-Cellular Therapies. (2023). Lumateperone Product Profile.
- MarketWatch. (2023). Pharmaceutical Pricing Trends.
